---
title: "Zhejiang Jolly Pharmaceutical Co.,Ltd. (300181.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300181.SZ.md"
symbol: "300181.SZ"
name: "Zhejiang Jolly Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T15:21:37.384Z"
locales:
  - [en](https://longbridge.com/en/quote/300181.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300181.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300181.SZ.md)
---

# Zhejiang Jolly Pharmaceutical Co.,Ltd. (300181.SZ)

## Company Overview

Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. The company also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, it offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.zuoli.com;http://www.jolly.com.cn](https://www.zuoli.com;http://www.jolly.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.31)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 28 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 14.10% |  |
| Net Profit YoY | 19.01% |  |
| P/B Ratio | 2.94 |  |
| Dividend Ratio | 4.13% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10031558701.63 |  |
| Revenue | 3108148942.98 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 19.88% | A |
| Profit Margin | 20.88% | A |
| Gross Margin | 63.83% | A |
| Revenue YoY | 14.10% | B |
| Net Profit YoY | 19.01% | B |
| Total Assets YoY | 16.66% | B |
| Net Assets YoY | 9.81% | B |
| Cash Flow Margin | 87.53% | C |
| OCF YoY | 14.10% | B |
| Turnover | 0.63 | B |
| Gearing Ratio | 34.47% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Jolly Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "14.10%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "19.01%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.94",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.13%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10031558701.63",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3108148942.98",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "19.88%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "20.88%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "63.83%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "14.10%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "19.01%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "16.66%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.81%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "87.53%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "14.10%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.63",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.47%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.51 | 20/215 | 22.27 | 20.41 | 19.14 |
| PB | 2.95 | 142/215 | 4.20 | 3.86 | 3.64 |
| PS (TTM) | 3.24 | 89/215 | 4.70 | 4.30 | 4.05 |
| Dividend Yield | 4.12% | 17/215 | 3.67% | 3.45% | 3.21% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.98 |
| Highest Target | 22.00 |
| Lowest Target | 22.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300181.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300181.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300181.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300181.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**